Valuation: Celsion Corporation

Market Cap 6.43M 5.64M 5.25M 4.83M 9.06M 614M 9.21M 62.33M 24.4M 305M 24.14M 23.62M 1.05B P/E 2026 *
-0.45x
P/E 2027 * -0.67x
Enterprise Value 6.43M 5.64M 5.25M 4.83M 9.06M 614M 9.21M 62.33M 24.4M 305M 24.14M 23.62M 1.05B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%+2.44%+53.17%+64.57% 56.19B
-1.32%-0.97%+38.41%+77.52% 54.83B
+1.49%+0.13%-18.03%-13.94% 23.04B
-0.57%-4.13%+2.34%+387.73% 22.7B
-0.21%+0.84%+22.48%-7.92% 20.23B
0.00%+3.30%+28.01%-29.07% 17.83B
-0.97%+0.89%+37.28%+539.62% 15.65B
-6.69%-5.11%+166.00%+304.89% 15.24B
+1.25%+0.69%+27.30%+184.69% 14.03B
Average -1.03%-0.02%+39.66%+167.56% 26.64B
Weighted average by Cap. -1.17%+0.42%+38.30%+130.82%

Financials

2026 *2027 *
Net sales - -
Net income -16.41M -14.4M -13.41M -12.33M -23.12M -1.57B -23.52M -159M -62.27M -777M -61.6M -60.27M -2.69B -23.33M -20.47M -19.06M -17.53M -32.87M -2.23B -33.43M -226M -88.53M -1.11B -87.58M -85.68M -3.82B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-